공시 • Apr 23
Resverlogix Corp., Annual General Meeting, Jun 25, 2026 Resverlogix Corp., Annual General Meeting, Jun 25, 2026. Location: alberta, calgary Canada 공시 • Nov 19
Resverlogix Appoints Bradley Glass to Board of Directors Resverlogix Corp. announced the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law. 공시 • Apr 23
Resverlogix Corp., Annual General Meeting, Jun 30, 2025 Resverlogix Corp., Annual General Meeting, Jun 30, 2025. Location: alberta, calgary Canada New Risk • Aug 16
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$78m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.1m). New Risk • Aug 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€11.9m market cap, or US$13.1m). New Risk • Jul 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€9.25m market cap, or US$10.0m). New Risk • Jul 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.21m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (€9.21m market cap, or US$10.00m). New Risk • Jun 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.25m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (€9.25m market cap, or US$9.99m). 공시 • Apr 20
Resverlogix Corp., Annual General Meeting, Jun 27, 2024 Resverlogix Corp., Annual General Meeting, Jun 27, 2024. New Risk • Apr 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.1m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-US$74m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (€10.3m market cap, or US$11.1m). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Director Shawn Lu was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Recent Insider Transactions • Jun 22
Co-Founder recently bought €68k worth of stock On the 17th of June, Donald McCaffrey bought around 372k shares on-market at roughly €0.18 per share. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of €73k worth in shares. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Lead Director Norma Biln was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Executive Departure • Jul 13
Senior Vice President of Business & Corporate Development Kenneth Lebioda has left the company On the 6th of July, Kenneth Lebioda's tenure as Senior Vice President of Business & Corporate Development ended. As of March 2021, Kenneth still personally held 186.45k shares (€109k worth at the time). Kenneth is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.75 years. Is New 90 Day High Low • Sep 19
New 90-day high: €0.58 The company is up 51% from its price of €0.39 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.